Idiosyncratic drug-induced liver injury imitates acute and chronic liver disease. The lack of pathognomonic diagnostic serological markers makes it under-recognized. Its consequences may range from being asymptomatic to self-limiting illness to severe liver injury causing acute liver failure. It is more common in Asia than in other parts of the world, mainly because of hepatotoxicity resulting from the treatment of tuberculosis disease and the ubiquitous use of traditional and complementary medicines in Asian countries. The APASL consensus guidelines on DILI explains various aspects including current evidence-based information on DILI with a focus on DILI due to antituberculosis agents and traditional and complementary medicine use in Asia.

Source: Hepatol Int. 2021;15(2):258-282. doi: 10.1007/s12072-021-10144-3.